Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.

A randomised, within patient comparison was made in patients with severe chronic heart failure, to study the acute haemodynamic effects of oral agents which have inotropic and vasodilator properties. A non-glycosidic non-adrenergic positive inotropic agent with vasodilator properties (amrinone) was compared with a beta-agonist which has vasodilator and positive inotropic effects (pirbuterol). To assess whether combined treatment with a venodilator might be advantageous, the effect of adding isosorbide dinitrate was studied. Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours. Control values before amrinone or pirbuterol were similar, and both drugs increased cardiac index while reducing left ventricular filling pressure, right atrial pressure, and systemic vascular resistance. Heart rate and blood pressure were unchanged. The magnitude of the changes caused by amrinone and pirbuterol were not significantly different. The addition of isosorbide dinitrate caused further falls in left ventricular filling pressure and right atrial pressures, and a fall in heart rate with each drug. Other measurements remained unchanged. Although amrinone and pirbuterol have different pharmacological properties, their acute haemodynamic effects in patients with chronic heart failure are indistinguishable.

[1]  E. Sonnenblick,et al.  Acute Substantial Benefit of Inotropic Therapy with Amrinone on Exercise Hemodynamics and Metabolism in Severe Congestive Heart Failure , 1981, Circulation.

[2]  P. Poole‐Wilson,et al.  Single-dose and dose-response studies with oral pirbuterol, a new beta agonist in chronic heart failure. , 1981, American heart journal.

[3]  D. Salsburg,et al.  Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. , 1981, American heart journal.

[4]  E. Braunwald,et al.  Problems in assessment of new pharmacologic agents for the heart failure patient. , 1981, American heart journal.

[5]  T. Brandon,et al.  Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts. , 1981, American heart journal.

[6]  A. Fishman,et al.  Amrinone and exercise performance in patients with chronic heart failure. , 1981, The American journal of cardiology.

[7]  E. J. Brown,et al.  Acute Effects of Oral Pirbuterol on Myocardial Oxygen Metabolism and Systemic Hemodynamics in Chronic Congestive Heart Failure , 1981, Circulation.

[8]  E. Sonnenblick,et al.  Relationship between amrinone plasma concentration and cardiac index , 1981, Clinical pharmacology and therapeutics.

[9]  P. Poole‐Wilson,et al.  Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. , 1981, British medical journal.

[10]  E. Sonnenblick,et al.  Beneficial Effects of Amrinone‐Hydralazine Combination on Resting Hemodynamics and Exercise Capacity in Patients with Severe Congestive Heart Failure , 1981, Circulation.

[11]  D. Mason,et al.  Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure. , 1981, The American journal of cardiology.

[12]  E. Braunwald,et al.  Effects of Amrinone on Myocardial Energy Metabolism and Hemodynamics in Patients with Severe Congestive Heart Failure Due to Coronary Artery Disease , 1980, Circulation.

[13]  E. Braunwald,et al.  Oral amrinone in refractory congestive heart failure. , 1980, The American journal of cardiology.

[14]  J. Edelson,et al.  High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog. , 1980, Journal of chromatography.

[15]  E. Sonnenblick,et al.  Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. , 1980, The American journal of cardiology.

[16]  S. Rubin,et al.  Thrombocytopenia and fever in a patient taking amrinone. , 1979, The New England journal of medicine.

[17]  R. Zelis,et al.  How much can we expect from vasodilator therapy in congestive heart failure? , 1979, Circulation.

[18]  E. Sonnenblick,et al.  Amrinone A New Non-Glycosidic, Non-Adrenergic Cardiotonic Agent Effective in the Treatment of Intractable Myocardial Failure in Man , 1979, Circulation.

[19]  E. Sonnenblick,et al.  Hemodynamic effects of intravenous and oral amrinone in patients with severe heart failure: relationship between intravenous and oral administration. , 1979, Transactions of the Association of American Physicians.

[20]  E. Braunwald,et al.  Hemodynamic assessment of amrinone. A new inotropic agent. , 1978, The New England journal of medicine.

[21]  G. Dennish,et al.  Vasodilator treatment for acute and chronic heart failure. , 1978, British heart journal.

[22]  A. Alousi,et al.  New cardiotonic agents: a search for digitalis substitute. , 1978, Life sciences.

[23]  S. Ayres,et al.  Effect of Dopamine on Hemodynamics and Myocardial Metabolism in Shock Following Acute Myocardial Infarction in Man , 1978, Circulation.

[24]  R. Miller,et al.  Importance of maintaining systemic blood pressure during nitroglycerin administration for reducing ischemic injury in patients with coronary disease. Effects on coronary blood flow, myocardial energetics and left ventricular function. , 1977, The American journal of cardiology.

[25]  J. Cohn,et al.  Comparative Hemodynamic Effects of Inotropic and Vasodilator Drugs in Severe Heart Failure , 1977, Circulation.

[26]  R. Miller,et al.  Pharmacological Mechanisms for Left Ventricular Unloading in Clinical Congestive Heart Failure: Differential Effects of Nitropmsside, Phentolamine, and Nitroglycerin on Cardiac Function and Peripheral Circulation , 1976, Circulation research.

[27]  S. Ayres,et al.  Effect of Isoproterenol, l‐Norepinephrine, and Intraaortic Counterpulsation on Hemodynamics and Myocardial Metabolism in Shock following Acute Myocardial Infarction , 1972, Circulation.

[28]  D T Mason,et al.  Usefulness and limitations of the rate of rise of intraventricular pressure (dp-dt) in the evaluation of myocardial contractility in man. , 1969, The American journal of cardiology.